Erythrocyte indices in the assessment of iron status in dialysis-dependent patients with end-stage renal disease on continuous erythropoietin receptor activator versus epoetin β therapy

Acta Haematologica

Volumn 124, Issue 1, 2010, Pages 27-33

  Jonckheere, Stijn ^a   Dierick, Jan ^a   Vanhouteghem, Hilde ^a   Devleeschouwer, Mieke ^a   Stove, Veronique ^b  

^a Algemeen Ziekenhuis Maria Middelares   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Continuous erythropoietin receptor activator; Dialysis; Epoetin ; Hypochromic red blood cells, percentage; Reticulocyte hemoglobin content

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; FERRIC HYDROXIDE SUCROSE; RECOMBINANT ERYTHROPOIETIN; IRON; MACROGOL DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MONITORING; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; IRON DEFICIENCY; IRON THERAPY; KIDNEY FAILURE; MALE; MEAN CORPUSCULAR VOLUME; PATIENT ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETICULOCYTE HEMOGLOBIN CONTENT; BLOOD; BLOOD EXAMINATION; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; INSTRUMENTATION; METHODOLOGY; PRACTICE GUIDELINE; RENAL REPLACEMENT THERAPY;

DRUG MONITORING; ERYTHROCYTE INDICES; ERYTHROPOIETIN, RECOMBINANT; HEMATOLOGIC TESTS; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; POLYETHYLENE GLYCOLS; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 77954188726     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000313785     Document Type: Article

References (21)

1. Rao M, Pereira BJ: Optimal anemia management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease. Kidney Int 2005; 68: 1432-1438.
2. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM: Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; 2: 1175-1178.
3. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-78.
4. Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U: Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007; 2: 637-646.
5. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19(suppl 2):ii1-ii47.
6. Brugnara C, Laufer MR, Friedman AJ, Bridges K, Platt O: Reticulocyte hemoglobin content (CHr): early indicator of iron deficiency and response to therapy. Blood 1994; 83: 3100-3101.
7. Brugnara C, Zelmanovic D, Sorette M, Ballas SK, Platt O: Reticulocyte hemoglobin: an integrated parameter for evaluation of erythropoietic activity. Am J Clin Pathol 1997; 108: 133-142.
8. Buttarello M, Temporin V, Ceravolo R, Farina G, Bulian P: The new reticulocyte parameter (RET-Y) of the Sysmex XE 2100: its use in the diagnosis and monitoring of posttreatment sideropenic anemia. Am J Clin Pathol 2004; 121: 489-495.
9. Brugnara C, Schiller B, Moran J: Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient states. Clin Lab Haematol 2006; 28: 303-308.
10. Maconi M, Cavalca L, Danise P, Cardarelli F, Brini M: Erythrocyte and reticulocyte indices in iron deficiency in chronic kidney disease: comparison of two methods. Scand J Clin Lab Invest 2009; 69: 365-370.
11. KDOQI, National Kidney Foundation: II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 2006; 47:S16-S85.
12. Levin NW, Fishbane S, Canedo FV, Zeig S, Nassar GM, Moran JE, Villa G, Beyer U, Oguey D: Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised noninferiority trial (MAXIMA). Lancet 2007; 370: 1415-1421.
13. Jarsch M, Brandt M, Lanzendorfer M, Haselbeck A: Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin- beta determined by surface plasmon res onance and competition binding assay. Pharmacology 2008; 81: 63-69.
14. Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, Dougherty FC, Reigner B: Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006; 1: 1211-1215.
15. Fishbane S, Pannier A, Liogier X, Jordan P, Dougherty FC, Reigner B: Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration. J Clin Pharmacol 2007; 47: 1390-1397.
16. Macdougall IC: Poor response to erythropoietin: practical guidelines on investigation and management. Nephrol Dial Transplant 1995; 10: 607-614.
17. Drueke T: Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 2001; 16(suppl 7):25-28.
18. Weiss G, Widner B, Zoller H, Schobersberger W, Fuchs D: Immune response and iron metabolism. Br J Anaesth 1998; 81(suppl 1):6-9.
19. Macdougall IC, Cooper AC: Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 2002; 17(suppl 11):39-43.
20. Nemeth E, Ganz T: The role of hepcidin in iron metabolism. Acta Haematol 2009; 122: 78-86.
21. Andrews NC: Molecular control of iron metabolism. Best Pract Res Clin Haematol 2005; 18: 159-169.